At the ARVO meeting in Seattle, Annexon Inc. presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy. ANX007, a non-pegylated antigen-binding fragment designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation, demonstrated broad-based protection against vision loss with statistically significant and dose dependent protection in BCVA ≥15-letter loss. The data also showed a 73% relative risk reduction in BCVA 15-letter loss, supporting time-dependent protection; a statistically significant slowing of low luminance visual acuity loss at month 12; and protection in both foveal and non-foveal patients from BCVA 15-letter loss.

In addition, ANX007 protected key retinal structures important for vision with a statistically significant reduction in photoreceptor loss through 12 months based on OCT Ellipsoid Zone assessment. The data also showed a greater slowing of RPE loss in patients with baseline foveal involvement compared to overall population (Fundus Autofluorescence Photography Assessment); and a >50% reduction in the number of patients with substantial retinal pigment epithelium loss in the fovea.

ANX007 was generally well-tolerated with no choroidal neovascularization increase in treated vs sham and no reported cases of vasculitis. For more, see the study results here.